Table 3 Patient characteristics

From: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

ID

Gender

Age (years)

Locoregional recurrence or metastasis of SCCHN

Localisation of metastases

Histological grading of squamous cell carcinoma

TNM stage at first diagnosis of SCCHN

Primary tumour site

ECOG performance status

02010001

Male

56

Distant metastasis

Liver

Unknown

T3N2M0

Pharynx

0

02010002

Female

43

Locoregional recurrence

Not applicable

Well differentiated

T1N0M0

Tongue

1

02010003

Male

56

Distant metastasis

Liver

Moderately differentiated

T4N2M1

Pharynx

0

03010001

Male

59

Locoregional recurrence

Not applicable

Unknown

TxNxMx

Tongue

1

03010002

Male

68

Locoregional recurrence

Not applicable

Well differentiated

T4N1M0

Pharynx

1

04010001

Male

54

Locoregional recurrence

Not applicable

Moderately differentiated

T4N1M0

Larynx

0

04010002

Male

74

Distant metastasis

Lung

Poorly differentiated

T4N3M1

Pharynx

1

04010004

Male

49

Distant metastasis

Cutaneous, skeletal, lymph nodes

Poorly differentiated

T4N3M0

Larynx

1

08010001

Male

32

Distant metastasis

Lung, hepatic, kidney

Poorly differentiated

T1N1M1

Tongue

0

08010002

Male

57

Locoregional recurrence

Not applicable

Well differentiated

T2N2M0

Tongue

1

  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group; SCCHN=squamous cell cancer of the head and neck; TNM = tumour node metastasis.